Modeling of pharmacokinetics of ganciclovir

Pharmacokinetics of ganciclovir by lung transplantation patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12622000645752

Enrollment

Registered

2022-05-03

Start date

2021-07-01

Completion date

Unknown

Last updated

2023-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The aim of this prospective study was to evaluate the pharmacokinetics of ganciclovir in lung transplant recipients and to explore its covariates and propose an individualized ganciclovir dosing regimen.

Interventions

Lung transplant patients receiving intravenous ganciclovir (5 mg/kg) twice daily for at least 48 hours after transplantation, blood samples will be collected and ganciclovir levels in the blood will be measured, The duration and frequency of observation in participants, 3-times for the first 24 hours and then in the sixth month post lung-transplant

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

had undergone lung transplantation and treated with intravenous ganciclovir twice daily for at least 48 hours after transplantation

Exclusion criteria

incomplete date

Outcome results